Karyopharm Selinexor Approval Likely Awaits BOSTON Trial, But US FDA Promises To Move Quickly

Oncologic Drugs Advisory Committee says Karyopharm’s multiple myeloma therapy is not ready for approval based on a single arm study. US FDA says it will move quickly when randomized trial is done.